SCHEMBL16665290

SCHEMBL16665290

Cc1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.68
MAPT P10636 6/20 0.68
LMNA P02545 3/20 0.68
MET P08581 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.50
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GPR119 Q8TDV5 2/20 0.49
PDK2 Q15119 1/20 0.48
HSP90AA1 P07900 1/20 0.48
GAA P10253 1/20 0.48
CYP2C19 P33261 2/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234962 0.96 ALDH1A1 (0.63) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL214341 0.91 MAPT (0.68) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL29803559 0.91 MAPT (0.68) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL16270620 0.90 MAPT (0.71) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL29858317 0.90 MAPT (0.71) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL5216622 0.88 MAPT (0.68) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL20339075 0.87 MAPT (0.67) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL16270621 0.87 MAPT (0.70) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL29355899 0.87 MAPT (0.67) ALDH1A1MAPTLMNAMETSMN1; SMN2
SCHEMBL28978026 0.87 MAPT (0.67) ALDH1A1MAPTLMNAMETSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024158872-A1 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF THE ROCKEFELLER UNIVERSITY (US) 2024-08-02 WO disclosed
US-20170360785-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-12-21 US disclosed
WO-2015057963-A1 FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360785-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 ALDH1A1 1012/4885MAPT 3917/4885LMNA 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.